A single injection of a gene therapy was well tolerated and showed the potential to control exudation in patients with neovascular age-related macular degeneration (wet AMD). A single subretinal dose ...

Oraya Therapeutics Inc. announced today that leading ophthalmologists from three European countries presented patient results following one year after a single treatment with Oraya Therapy for wet age ...

A novel treatment that uses a disintegrating matrix for sustained release of medication led to improvement in vision and reduced supplemental treatment in patients with diabetic macular edema, ...

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ...

-- Patients Receiving Single Intravitreal Injection of ADVM-022 Dosed at 2 x 10^11 vg/eye MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical ...

Oraya Therapeutics Inc. announced today at the Royal College of Ophthalmologists Annual Congress that U.K. ophthalmologists are the leading adopters of Oraya Therapy for the treatment of wet ...

Adverum Biotechnologies (ADVM) has made great progress lately in advancing the use of its gene therapy, known as ixoberogene soroparvovec [Ixo-vec], which is being developed for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . One specialist argued that, in the future, gene therapy technologies will be the favored option for wet AMD.

4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results ...

The American Society of Retina Specialists annual meeting featured study results and research in age-related macular degeneration. In one presentation, a large ongoing real-world study of faricimab ...